Treatment strategy for acute uncomplicated urinary tract infections in women

1. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М.; 2017. [Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. Moscow; 2017. (in Russian)]

2. Naber K.G., Schito G., Botto H., Palou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur. Urol. 2008; 54(5): 1164-75.

3. European Association of Urology. EAU Guidelines urological infections; update 2017; 3.4.1. Available at: www.uroweb.org

4. Lutay N., Ambite I., Grönberg Hernandez J., Rydström G., Ragnarsdóttir B., Puthia M. et al. Bacterial control of host geneexpression through RNA polymerase II. J. Clin. Invest. 2013; 123(6): 2366-79.

5. Cai T., Mazzoli S., Mondaini N., Meacci F., Nesi G., D'Elia C. et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or not to treat? Clin. Infect. Dis. 2012; 55(6): 771-7.

6. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016. 480с. [Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu., ed. Urology. Clinical recommendations. Moscow: GEOTAR-Media; 2016. 480p. (in Russian)]

7. Köves B., Cai T., Veeratterapillay R., Pickard R., Seisen T., Lam T.B. et al. Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur. Urol. 2017; 72(6): 865-8.

8. Зайцев А.В., Тупикина Н.В. Рецидивирующая инфекция мочевых путей - междисциплинарная проблема. Медицинский совет. 2014; 19: 36-44. [Zaitsev A.V., Tupikina N.V. Recurrent urinary tract infection is an interdisciplinary problem. Meditsinskiy sovet. 2014; 19: 36-44. (in Russian)]

9. Ho P.L., Wong R.C., Yip K.S., Loke S.L., Leung M.S., Mak G.C. et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn. Microbiol. Infect. Dis. 2007; 59(4): 439-45.

10. Gagliotti C., Buttazzi R., Sforza S., Moro M.L.; Emilia-Romagna Antibiotic Resistance Study Group. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J. Infect. 2008; 57(3): 179-84.

11. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Фосфомицин в сравнении с другими антибиотиками, применяемыми в лечении цистита – мета анализ рандомизированных контролируемых исследований. Экспериментальная и клиническая урология. 2013; 1: 94-102. [Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Phosphomycin in comparison with other antibiotics used in the treatment of cystitis-meta analysis of randomized controlled trials. Eksperimental'naya i klinicheskaya urologiya. 2013; 1: 94-102. (in Russian)]

12. Falagas M.E., Roussos N., Gkegkes I.D., Rafailidis P.I., Karageorgopoulos D.E. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin. Investig. Drugs. 2009;18(7): 921-44.

13. Bishop M.C. Uncomplicated urinaru tract infection. EAU Updated Series. 2014; 2(3): 143-50.

14. Falagas M.E., Kastoris A.C., Karageorgopoulos D.E., Rafailidis P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of Systematic review 1875 JAC by guest on October 6, 2012. Available at: http://jac.oxfordjournals.org/ Downloaded from microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 2009; 34(2): 111-20.

15. Wagenlehner F.M., Thomas P.M., Naber K.G. Fosfomycin trometamol (3.000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol. Int. 2014; 92(2): 125-30.

16. Палагин И.С., Cухорукова М.В., Гринев А.В., Перепанова Т.С., Козлов Р.С. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследований. Клиническая микробиология и антимикробная химиотерапия. 2012; 14(4): 280-302. [Palagin I.S., Suhorukova M.V., Grinev A.V., Perepanova T.S., Kozlov R.S. The current state of antibiotic resistance of pathogens of community-acquired infections of the urinary tract in Russia: the results of research. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2012; 14(4): 280-302. (in Russian)]

17. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2010; 65(9): 1862-77.

18. Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., Hooton T.M. Infectious Diseases Society of America guidelines for the diagnosis and treatment bacteriuria in adults. Clin. Infect. Dis. 2015: 40(5): 643-54.

19. European Association of Urology. EAU Guidelines urological infections; update 2017; 3.4.5. Available at: www.uroweb.org

20. Алиджанов Ж.Ф. Существуют ли альтернативные методы антибактериальной терапии и профилактики неосложненных инфекций мочевыводящих путей? Урология. 2014; 6: 5-13. [Alidzhanov Zh.F. Are there alternative methods for antibiotic therapy and prevention of uncomplicated urinary tract infections? Urologiya. 2014; 6: 5-13. (in Russian)]

21. Зайцев А.В., Колонтарев К.Б. Роль фосфомицина в лечении инфекций мочевыводящих путей. Урология. 2017; 4: 91-6. [Zaitsev A.V., Kolontarev K.B. The role of phosphomycin in the treatment of urinary tract infections. Urologiya. 2017; 4: 91-6. (in Russian)]

Received 08.06.2018

Accepted 22.06.2018